Published: October 2023
On 30 October 2023, Merck KGaA entered into an agreement with Hengrui with an aim to develop and commercialize next-generation selective PARP1 inhibitor HRS-1167 and Claudin18.2 antibody-drug conjugate SHR-A1904. The company aims to utilize Hengrui’s internal DNA damage response expertise and in-house ADC capabilities.
Additionally, Merck KGaA aims to provide Hengrui with an upfront payment of €160 million which will be utilized in development, regulatory and commercial milestones. Potential payments are estimated to reach over €1.4 billion.
According to Roots Analysis, the Antibody Drug Conjugates Market is estimated to be worth $7.72 billion in 2023 and is expected to grow at a CAGR of 9.6% during the forecast period.
For detailed insights about this domain, check out our report on Antibody Drug Conjugates Market or email email@example.com
You may also be interested in the following titles:
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES